[HTML][HTML] Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a sco** review
The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …
[HTML][HTML] Measuring financial toxicity in head and neck cancer: a systematic review
E Raggini, D Mattavelli, G Zigliani, P Bossi… - Acta …, 2024 - ncbi.nlm.nih.gov
Objective The current study systematically reviews the literature about financial toxicity (FT)
in head and neck cancer patients. Three databases were reviewed: PubMed, Scopus and …
in head and neck cancer patients. Three databases were reviewed: PubMed, Scopus and …
Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment
Introduction Financial toxicity is common and pervasive among cancer patients. Research
suggests that gynecologic cancer patients experiencing financial toxicity are at increased …
suggests that gynecologic cancer patients experiencing financial toxicity are at increased …
Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity
Background Financial toxicity describes the impairment of financial wellbeing in patients due
to the burden of cancer diagnosis and care. The COST: A Functional Assessment of Chronic …
to the burden of cancer diagnosis and care. The COST: A Functional Assessment of Chronic …
[HTML][HTML] Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials?
Background Financial difficulties in relation with diagnosis and treatment of patients with
cancer affects their quality-of-life (QoL). We aim to characterize how financial toxicity was …
cancer affects their quality-of-life (QoL). We aim to characterize how financial toxicity was …
[HTML][HTML] ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer
Background Financial toxicity, defined as both the objective financial burden and subjective
financial distress from a cancer diagnosis and its treatment, is a topic of interest in the …
financial distress from a cancer diagnosis and its treatment, is a topic of interest in the …
Financial toxicity and health-related quality of life profile of patients with hematologic malignancies treated in a universal health care system
PURPOSE We investigated the association of financial toxicity (FT) with the health-related
quality of life (HRQoL) profile of patients with hematologic malignancies treated in a …
quality of life (HRQoL) profile of patients with hematologic malignancies treated in a …
[HTML][HTML] Cross-cultural adaptation of the PROFFIT Instrument to measure financial toxicity in people living with cancer within a UK population
Background This study aimed to develop a British version of the Patient Reported Outcomes
for Fighting Financial Toxicity of Cancer (PROFFIT): originally designed to measure financial …
for Fighting Financial Toxicity of Cancer (PROFFIT): originally designed to measure financial …
Financial hardship among siblings of long‐term survivors of childhood cancer: A Childhood Cancer Survivor Study report
Background Siblings of children with cancer may experience adverse household economic
consequences, but their financial outcomes in adulthood are unknown. Methods A total of …
consequences, but their financial outcomes in adulthood are unknown. Methods A total of …
Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers
K Spencer, H Butenschoen, E Alger… - American Society of …, 2024 - ascopubs.org
Dose-finding oncology trials (DFOTs) provide early access to novel compounds of potential
therapeutic benefit in addition to providing critical safety and dosing information. While …
therapeutic benefit in addition to providing critical safety and dosing information. While …